Lucie Bruijn, Robin Conwit, Flint Beal, Gilmore O'Neill, Susan C. Fagan and Merit E. Cudkowicz
Submitted September 20, 2006
We thank Dr. Burke for his comments concerning the possible role of taxol as a treatment for ALS. The purpose of our article is to facilitate development of a
systematic and rational selection process to determine which candidate
agents should be prioritized for clinical trials in ALS patients and to
stimulate debate on this issue among the ALS research community.
The priority
list outlined in our manuscript is dynamic and will be updated annually as
additional data on both existing and novel neuroprotective agents becomes
available. [1] Therefore, we look forward to evaluating taxol as well as
other agents that have a potentially beneficial effect on disease
progression in ALS.
We thank Dr. Burke for his comments concerning the possible role of taxol as a treatment for ALS. The purpose of our article is to facilitate development of a systematic and rational selection process to determine which candidate agents should be prioritized for clinical trials in ALS patients and to stimulate debate on this issue among the ALS research community.
The priority list outlined in our manuscript is dynamic and will be updated annually as additional data on both existing and novel neuroprotective agents becomes available. [1] Therefore, we look forward to evaluating taxol as well as other agents that have a potentially beneficial effect on disease progression in ALS.
Reference
1. Traynor BJ, Bruijn L, Conwit R, Beal F, O’Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS. Neurology 2006; 67:20-27.
Disclosure: The authors report no conflicts of interest.